Gregory Bonfiglio
Director/Board Member at HEALIOS K.K.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Masanori Sawada | M | 42 | 12 years | |
Hardy Kagimoto | M | 47 | 13 years | |
Richard Kincaid | M | 47 | 6 years | |
Mark Surfas | M | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | 19 years |
Yoshinari Matsuda | M | 45 | 11 years | |
Jun Narimatsu | M | 55 | 11 years | |
Michael J. Alfant | M | 63 | 11 years | |
Clive Svendsen | M | - |
The International Society for Stem Cell Research
| 2 years |
David W. Smith | M | 63 | 6 years | |
Peretz Partensky | M | - |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | 6 years |
Kouichi Tamura | M | 67 | 10 years | |
David A. Frosh | M | 65 |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Seigo Kashii | M | 70 | 7 years | |
John David Sinden | M | 73 |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States.
The International Society for Stem Cell Research
| - |
Jesse Cotari | M | - |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | 6 years |
Claudia L Llanos | F | - |
Anthem Venture Management LLC
Anthem Venture Management LLC Investment ManagersFinance Anthem Venture Management LLC (Anthem Venture Management) is a venture capital firm founded in 2000. The firm is headquartered in Santa Monica, California. | 23 years |
Lok Chung Chan | M | 73 |
The International Society for Stem Cell Research
| 16 years |
Dylan Morris | M | - |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | 1 years |
Kurt C. Gunter | M | 69 |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Kilian Kelly | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Vladislav Sandler | M | 59 |
The International Society for Stem Cell Research
| - |
Kenneth S. Zaret | M | - |
The International Society for Stem Cell Research
| - |
Jason Livingston | M | 53 |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Alicia Marie Jackson | M | - |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | - |
Chuck Murry | M | 64 |
The International Society for Stem Cell Research
| - |
Ralph T. Salvagno | M | 69 |
The International Society for Stem Cell Research
| - |
Konrad Hochedlinger | M | - |
The International Society for Stem Cell Research
| - |
Russell Kern | M | 38 |
The International Society for Stem Cell Research
| - |
Anish Majumdar | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Jurgen Knoblich | M | - |
The International Society for Stem Cell Research
| - |
Melissa Little | F | - |
The International Society for Stem Cell Research
| - |
Valentina Greco | M | - |
The International Society for Stem Cell Research
| 2 years |
Helen Blau | F | - |
The International Society for Stem Cell Research
| 2 years |
Kathy Niakan | F | - |
The International Society for Stem Cell Research
| 2 years |
Karen M. Nichols | F | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | 17 years |
Robert McEwen | M | 74 |
The International Society for Stem Cell Research
| - |
Douglas A. Melton | M | 70 |
The International Society for Stem Cell Research
| - |
Melissa K. Carpenter | M | - |
The International Society for Stem Cell Research
| 3 years |
Paul Kosnik | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Mercy Udoh | F | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Aleksandra J. Poole | M | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Craig T. Fredrickson | M | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Monica M. Siegenthaler | M | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Wai Yeng Chong | F | 60 |
The International Society for Stem Cell Research
| - |
Yann Godfrin | M | 52 |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Fred Gage | M | - |
The International Society for Stem Cell Research
| - |
Richard E. Kruger | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Arnold Kriegstein | M | - |
The International Society for Stem Cell Research
| - |
Uriel Barkai | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Gernalia Satianegara | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Kenneth L. Berger | M | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Gabriel I. Nistor | M | - |
NeoStem Oncology LLC
NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Burton Feinerman | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Kim Warren | M | - |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | - |
Stewart Craig | M | 63 |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Merri Buff Mair | M | - |
International Society for Cellular Therapy
International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Brian Underdown | M | 83 |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | 12 years |
H. Ralph Snodgrass | M | 74 |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | 13 years |
Keith M. Swaffar | M | - |
Michigan State University
| 6 years |
Thomas E. Hebel | M | 73 |
Michigan State University
| 5 years |
Chris Mason | M | - |
Proteus RM LLC (Venture Capital)
Proteus RM LLC (Venture Capital) Investment ManagersFinance Proteus RM LLC (Venture Capital) (Proteus RM) is a venture capital subsidiary of Proteus RM LLC founded in 2006 by Gregory A. Bonfiglio. The firm is headquartered in Portola Valley, California. | 10 years |
Rick Sirvatis | M | - |
Michigan State University
| 6 years |
Thomas E. Klema | M | 70 |
Michigan State University
| 5 years |
A. Franklin Rice | M | 70 |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | 12 years |
Shawn Singh | M | 61 |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | 11 years |
Dennis A. Zalupski | M | - |
Michigan State University
| 6 years |
Jerrold Dotson | M | 71 | 12 years | |
David Thompson | M | 76 |
Michigan State University
| 6 years |
Dieter L. Pape | M | 77 |
Michigan State University
| 6 years |
John R. Nyland | M | - |
Michigan State University
| 6 years |
Donald G. Fortunate | M | - |
Michigan State University
| 10 years |
Cheryl A. Gorman | F | - |
The University of Michigan Law School
Michigan State University
| 7 years |
Kin Keung Lai | M | 73 |
Michigan State University
| 4 years |
Stephen J. Morrow | M | - |
Michigan State University
| 7 years |
Enoch C. Jen | M | 72 |
Michigan State University
| 5 years |
Robert W. Rubin | M | - |
Michigan State University
| 2 years |
John C. Collins | M | - |
Michigan State University
| 6 years |
Kathleen A. Lang | F | - |
Michigan State University
| 4 years |
Judy A. O'Neill | F | - |
Michigan State University
| 4 years |
Pat Leblanc | M | - |
Michigan State University
| 4 years |
Chris E. Rossman | M | - |
Michigan State University
| 4 years |
Bob Maginn | M | - |
Michigan State University
| 2 years |
Theodore E. Maione | M | - |
Michigan State University
| 4 years |
Dennis Ray Konczal | M | - |
Michigan State University
| 4 years |
J. Mark Bronson | M | 75 |
Michigan State University
| 2 years |
Richard Wayne Riley | M | - |
Michigan State University
| 4 years |
Nell Anne Hennessy | F | - |
Michigan State University
| 4 years |
Paul G. Anthes | M | - |
Michigan State University
| 4 years |
Gary Mize | M | 73 |
Michigan State University
| 4 years |
Zeke M. Fleet | M | - |
Michigan State University
| 4 years |
Tim R. Oren | M | - |
Michigan State University
| 3 years |
D. Ry Wagner | M | - |
Michigan State University
| 4 years |
Karen Maria Alida de Segundo | M | 77 |
Michigan State University
| 2 years |
Tom J. Borelli | M | - |
Michigan State University
| 4 years |
Bruce A. Ferguson | M | - |
Michigan State University
| 4 years |
Dennis P. McCrary | M | - |
Michigan State University
| 4 years |
H. Krimbill | M | 70 |
Michigan State University
| 4 years |
Nicholas L. Blauwiekel | M | 68 |
Michigan State University
| 4 years |
Ken S. Bajaj | M | - |
Michigan State University
| 3 years |
Forrest James E. | M | - |
Michigan State University
| - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 79 | 79.00% |
Canada | 13 | 13.00% |
Japan | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gregory Bonfiglio
- Personal Network